Loading...
ALT logo

Altimmune, Inc.NasdaqGM:ALT 株式レポート

時価総額 US$554.3m
株価
US$2.85
US$28
89.8% 割安 内在価値ディスカウント
1Y-48.2%
7D-7.8%
ポートフォリオ価値
​
表示

Altimmune, Inc.

NasdaqGM:ALT 株式レポート

時価総額：US$554.3m

Altimmune（ALT）株式概要

後期臨床段階のバイオ医薬品企業であるアルティミューン社は、重篤な肝疾患に対する新規治療法の開発に注力している。 詳細

ALT ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長2/6
過去の実績0/6
財務の健全性5/6
配当金0/6

報酬

収益は年間74.16%増加すると予測されています

リスク分析

今後3年間の収益は年平均10.6%減少すると予測されている。

収益が 100 万ドル未満 ( $36K )

過去1年間で株主の希薄化は大幅に進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない


ALT Community Fair Values

Create Narrative

See what 40 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Altimmune, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Altimmune
過去の株価
現在の株価US$2.85
52週高値US$7.73
52週安値US$2.56
ベータ0.17
1ヶ月の変化-18.57%
3ヶ月変化-36.67%
1年変化-48.18%
3年間の変化-36.38%
5年間の変化-76.35%
IPOからの変化-98.80%

最新ニュース

Seeking Alpha • Apr 09

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Summary Altimmune has announced it expects to produce topline data from its phase 2 RECLAIM study of pemvidutide in alcohol use disorder. ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway extends into 2028, but further ATM usage or offerings could suppress share price rallies and introduce dilution risk. ALT's RECLAIM study is not without a chance of success, other incretins have shown promise in alcohol use disorder previously. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 09

Altimmune: Considering If A Repeat Of The 2025 Run-Up Is On Tap

Summary Altimmune has announced it expects to produce topline data from its phase 2 RECLAIM study of pemvidutide in alcohol use disorder. ALT is planning to start a large phase 3 of pemvidutide in MASH in 2026, although it hasn't provided a more specific timeline than that. ALT's $340M cash runway extends into 2028, but further ATM usage or offerings could suppress share price rallies and introduce dilution risk. ALT's RECLAIM study is not without a chance of success, other incretins have shown promise in alcohol use disorder previously. Read the full article on Seeking Alpha
Seeking Alpha • Mar 17

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine

Summary Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025. Pemvidutide is also being developed for patients with obesity; ALT received clearance from the FDA to run four phase 3 studies for possible eventual marketing approval in targeting these patients. Read the full article on Seeking Alpha
Seeking Alpha • Feb 28

Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2

Summary Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success. Investors should watch for the Phase 2b IMPACT study results in Q2 2025, which could significantly impact Altimmune's stock and future prospects in the MASH market. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

Altimmune's Catalytic Moment In 2025: Pemvidutide's Phase 2b Trial In MASH

Summary Altimmune is a single-molecule company currently trading at a $0.5 billion market cap with a favorable risk-reward profile. The company's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH (metabolic dysfunction-associated steatohepatitis). Pemvidutide has successfully completed a Phase 1 trial for a related liver disease but has yet to demonstrate efficacy in the target indication of MASH. Direct peers such as Akero Therapeutics and Madrigal have more advanced clinical trials and are valued at $2 billion and $7 billion, respectively, implying significant upside potential for ALT stock. Comparable catalysts for MASH show that Altimmune, with positive Phase 2 data, could experience a market cap expansion of $475 million, equating to an almost 80% upside. Read the full article on Seeking Alpha
分析記事 • Jan 15

Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Dec 30

Altimmune Could Find A Partner For Its Phase 3 Exercise

Summary ALT's end-of-phase 2 meeting with the FDA provided a clear clinical plan for pemvidutide, but the phase 3 program will require 5,000 patients. ALT's $139M in cash is enough to stay afloat for a while at the current rate, but not to fund phase 3, the company needs a partner or a buyout. If ALT can't find a partner or be acquired, then a hefty fund raise awaits investors, which could hit the stock. Despite competition, the potential for a partnership or buyout remains strong, as Big Pharma continues to show interest in weight loss drugs, and ALT seems cheap compared to its peers. Read the full article on Seeking Alpha
Seeking Alpha • Dec 16

Altimmune 2025: Redefining Obesity And MASH Treatment

Summary Altimmune is entering both obesity and MASH markets with a powerful GLP-1/Glucagon dual-agonist drug called Pemvidutide, offering fat-specific weight loss and muscle preservation with a strong safety profile. Altimmune is redefining success in both obesity and MASH to position Pemvidutide in "blue ocean" categories not addressed by incumbents and catered to the unique strengths of Glucagon in Pemvidutide. Valuation of on-label and off-label use of Pemvidutide across all indications and comorbidities show that Altimmune is significantly undervalued at current share prices, factoring in all risks. Read the full article on Seeking Alpha
Seeking Alpha • Nov 13

Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Summary Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial for obesity demonstrated significant weight loss and lean mass preservation, with up to 15.6% weight reduction at the highest dose. Altimmune’s cash runway is estimated to support operations into 1H2026, aligning with expected milestones and anticipated Phase 3 trials. The company plans to expand Pemvidutide’s applications with a new IND for additional indications by year-end, enhancing its market potential. Thus, I am upgrading ALT stock to a “Strong Buy” due to the promising progress of its lead drug candidate, sufficient runway, and several future catalysts. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Regulatory And Clinical Catalysts Ahead For Altimmune

Summary ALT is developing pemvidutide for obesity and liver diseases, with recent MOMENTUM sub-study results showing favorable body composition results. A readout from the Phase 2b trial of pemvidutide in MASH is delayed to Q2'25, although the trial has completed enrollment, making further delays unlikely. ALT has $164.9M in cash but may need additional funding for phase 3 trials; a partnership for phase 3 development in obesity remains a possibility. Read the full article on Seeking Alpha
Seeking Alpha • Oct 02

Consider Buying Potential Takeover Target Altimmune

Summary Altimmune, Inc.'s weight loss drug, pemvidutide, shows significant superiority in lean mass retention and liver fat reduction, making it a potential takeover target. High short interest in Altimmune stock could trigger a short-covering rally if reports of takeover talks emerge. Pemvidutide's superior lean mass retention could enable it to capture market share from Novo Nordisk's Wegovy and Eli Lilly's tirzepatide. Read the full article on Seeking Alpha
Seeking Alpha • Sep 21

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

Summary Pemvidutide shows strong potential in obesity and MASH, preserving lean mass while reducing VAT, which could make it a market leader among GLP-1s. Recent Phase II data reveals pemvidutide's lean loss ratio of 21.9%, comparable to diet and exercise, and significant VAT reduction, enhancing its appeal. Despite competition and risks, I am bullish on ALT, upgrading my conviction rating and planning to add to my position below $8.20 per share. Pemvidutide's dual indications for obesity and MASH, along with potential cardiovascular benefits, could drive Altimmune to blockbuster status and significant revenue growth. Read the full article on Seeking Alpha
分析記事 • Sep 12

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Altimmune ( NASDAQ:ALT...
Seeking Alpha • Aug 27

Altimmune: Emerging Position In Competitive Space, But Risks Remain

Summary Weight loss drugs like Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide dominate the market, with Novo Nordisk leading in sales and Amgen developing a novel competitor. Altimmune’s pemvidutide shows promising weight loss and lean mass preservation but faces high discontinuation rates and lacks sugar control, unlike rivals. Financially, Altimmune has a cash runway of five to six quarters, necessitating a likely dilution before their phase 3 trial's completion. Despite promising data, Altimmune's pemvidutide faces tough competition from established players, making it a risky investment without more differentiating metrics. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Altimmune: Lean Muscle Fat Data Sends Stock Soaring - Competitors Will Take Note

Summary Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, which have demonstrated miraculous weight loss improvements, and will likely dominate a ~$130bn market. Altimmune's latest data shows significant weight loss and lean muscle preservation - the latter may be most significant. If pemvidutide can show it removes less lean muscle fat than competing GLP-1 agonist drugs, it may be on a fast track to approval and a double-digit billion dollar revenue opportunity. It is not quite so simple as it sounds, however - other candidates are yet to fully show their hands, and Altimmune is a minnow compared to the large pharmas crowding this space. Nevertheless, it is an interesting development. Read the full article on Seeking Alpha
Seeking Alpha • May 27

Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns

Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a significant opportunity for Altimmune. Altimmune needs to find a partnership to compete with established players like Novo Nordisk and Eli Lilly, but the potential of Pemvidutide is high, making it a buy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 12

Buy Altimmune's Potential Market Disruption With Pemvidutide

Summary Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown promising results in clinical trials for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and the company is seeking partnerships for further development. ALT's strategic shift includes partnering discussions to enhance Pemvidutide's development pathway and potential commercialization. Overall I think ALT is a viable investment for investors who are aware of the inherent risks in biotech. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place

Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion by 2030. Results from the phase 2b IMPACT study, using pemvidutide for the treatment of patients with MASH, expected to be released Q1 of 2025. Altimmune had $198 million in cash as of December 31st of 2023; It will likely have to continue to tap into the ATM agreement or find another way to raise cash to fund its pipeline. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally

Summary Altimmune's stock price has experienced extreme volatility, but jumped by >20% yesterday due to the potential of pemvidutide, a drug candidate for obesity and liver disease. Some analysts believe pemvidutide can have a similar impact as Eli Lilly's tirzepatide and Novo Nordisk's semaglutide on these two indications - both Pharma's share prices have been soaring. Altimmune's previous COVID and anthrax vaccine efforts were unsuccessful, but there is optimism - based on some promising data - that pemvidutide could be different and provide a valuable opportunity. Ultimately, however, with its drug having some problematic side effects and the company struggling for funding, I'm giving Altimmune the thumbs down. There is a data readout in relation to a Hepatitis B therapy due this quarter - a small hedge against pemvidutide struggles - many will disagree, but selling after the recent bull run may be the right option. Read the full article on Seeking Alpha
Seeking Alpha • Feb 12

Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment

Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon agonist, despite existing competition. Pemvidutide demonstrated dose-dependent weight loss in Phase 2, but high adverse event rates, especially gastrointestinal, led to notable discontinuation. Financially, Altimmune holds a strong current ratio with a 21-month runway despite the need for future capital to sustain operations. Investment Recommendation: Hold ALT stock due to the balance between pemvidutide's potential and its competition, tolerability concerns, and financial health. Read the full article on Seeking Alpha
分析記事 • Feb 10

Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 10

Thoroughly Derisked, Altimmune Is Now A Great Buy

Summary Altimmune's weight loss drug, Pemvidutide, showed promising results in a phase 2 trial, with a mean weight loss of 15.6% at week 48. The drug also demonstrated better CV risk reduction, lipid changes and tolerability than its competitors, semaglutide and tirzepatide. Altimmune's stock is undervalued compared to the potential market success of a weight loss drug, with potential for significant upside. Read the full article on Seeking Alpha
分析記事 • Oct 11

Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Jun 27

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Feb 12

Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

株主還元

ALTUS BiotechsUS 市場
7D-7.8%-1.8%-0.3%
1Y-48.2%32.7%24.1%

業界別リターン: ALT過去 1 年間で32.7 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: ALTは、過去 1 年間で24.1 % のリターンを上げたUS市場を下回りました。

価格変動

Is ALT's price volatile compared to industry and market?
ALT volatility
ALT Average Weekly Movement10.6%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

安定した株価: ALT 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: ALTの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
199757Jerry Dursoaltimmune.com

後期臨床段階のバイオ医薬品会社であるアルティミューン社は、重篤な肝疾患に対する新規治療法の開発に注力している。同社の主力製品候補はGLP-1/グルカゴン二重受容体作動薬であるペムビデュチドで、代謝機能障害関連脂肪肝炎、アルコール使用障害、アルコール関連肝疾患の治療薬として第3相臨床試験中である。同社は1997年に設立され、メリーランド州ゲイサーズバーグに本社を置いている。

Altimmune, Inc. 基礎のまとめ

Altimmune の収益と売上を時価総額と比較するとどうか。
ALT 基礎統計学
時価総額US$554.25m
収益（TTM）-US$91.08m
売上高(TTM)US$36.00k
Over9,999x
P/Sレシオ
-6.1x
PER（株価収益率

ALT は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ALT 損益計算書（TTM）
収益US$36.00k
売上原価US$66.09m
売上総利益-US$66.05m
その他の費用US$25.03m
収益-US$91.08m

直近の収益報告

Mar 31, 2026

次回決算日

該当なし

一株当たり利益（EPS）-0.47
グロス・マージン-183,477.78%
純利益率-253,002.78%
有利子負債／自己資本比率12.2%

ALT の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/18 08:26
終値2026/05/15 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Altimmune, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19

アナリスト機関
Eliana MerleBarclays
William WoodB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.